Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Researchers Solve a Mystery about Type 2 Diabetes Drug

Published: Friday, November 22, 2013
Last Updated: Friday, November 22, 2013
Bookmark and Share
AB SCIEX TripleTOF® and QTRAP® technologies support breakthrough medical study.

Researchers from St. Vincent’s Institute of Medical Research in Melbourne, Australia, in collaboration with researchers at McMaster University in Canada, are reportedly the first to discover how the type 2 diabetes drug metformin actually works, providing a molecular understanding that could lead to the development of more effective therapies. Mass spectrometry technologies from AB SCIEX played a critical role in the analysis that led to this breakthrough finding.  The research is published in this month’s issue of the journal Nature Medicine.  

Doctors have known for decades that metformin helps treat type 2 diabetes.  However, questions had lingered for more than 50 years whether this drug, which is available as a generic drug, worked to lower blood glucose in patients by directly working on the glucose. People with type 2 diabetes have high blood sugar levels and have trouble converting sugar in their blood into energy because of low levels of insulin. For treating this condition, metformin is considered the most widely prescribed anti-diabetic drug in the world.  

Until now, no one had been able to explain adequately how this drug lowers blood sugar. According to this new study, the drug works by reducing harmful fat in the liver. People who take metformin reportedly often have a fatty liver, which is frequently caused by obesity.  

“Fat is likely a key trigger for pre-diabetes in humans,” said Professor Bruce Kemp, PhD, the Head of Protein Chemistry and Metabolism at St. Vincent’s Institute of Medical Research.  “Our study indicates that metformin doesn’t directly reduce sugar metabolism, as previously suspected, but instead reduces fat in the liver, which in turn allows insulin to work effectively.”  

The breakthrough in pinning down how the drug functions began with the researchers making genetic mutations to the genes of two enzymes, ACC1 and ACC2, in mice, so they could no longer be controlled.  What happened next surprised the researchers: the mice didn’t get fat as expected, but Associate Professor Gregory Steinberg, PhD at McMaster University noticed that the mice had fatty livers and a pre-diabetic condition. Then the researchers put the mice on a high fat diet and they became fat, while metformin did not lower the blood sugar levels of the mutant mice. 

The findings are expected to help researchers better directly target the condition, which affects over 100 million people around the world, according to published reports. It is also believed that with the mystery of metformin solved, the application of the drug could go beyond just diabetes and potentially be used to treat other medical conditions. 

“AB SCIEX mass spectrometry solutions help researchers explore big questions and conduct breakthrough studies, such as this remarkable type 2 diabetes study,” said Rainer Blair, President of AB SCIEX.   “In order to understand disease at the molecular level, researchers need the sensitive detection and reproducible quantitation provided by AB SCIEX tools. We enable the research community to solve biological mysteries and rethink the possibilities to transform health.”

For the research conducted by the Australian and Canadian researchers, the analysis at the molecular level was optimized on AB SCIEX instrumentation, including the AB SCIEX TripleTOF® 5600 and the AB SCIEX QTRAP® 5500 system.  The TripleTOF system, with its high-speed, high-quality MS/MS capabilities, was used for the discovery of key proteins and phosphopeptides.  The QTRAP system, with its high sensitivity MRM (multiple reaction monitoring) capabilities, was used for quantitation of metabolites, including nucleotides and malonyl-CoA.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCIEX and Hepregen Announce Co-Marketing Agreement
Alliance establishes SCIEX and Hepregen as a one-stop solution provider for drug metabolism investigators.
Friday, May 22, 2015
Sciex, Hepregen Team up on Metabolite Identification Offering
This recently announced collaboration aims to provide practical solutions for drug metabolism researchers.
Thursday, May 21, 2015
SCIEX and Mass Consortium Corporation Announce Exclusive Reseller Agreement
SCIEX to provide customers with XCMSplus software solution for simplified and accelerated metabolomics workflows.
Tuesday, March 31, 2015
AB SCIEX Wins New Product Innovation Award in Asia Pacific
The award recognizes the company’s continued innovation in the mass spectrometry industry and a number of new products introduced into the market in recent years.
Thursday, October 30, 2014
Barry Karger Receives Arnold O. Beckman Award
Award honors Prof Karger for his outstanding achievements in the field of electrodriven separation techniques.
Monday, April 28, 2014
AB SCIEX Expands Support in the Middle East
AB SCIEX announces the opening of a new regional office and technical support centre located in Dubai.
Tuesday, October 29, 2013
AB SCIEX Receives Frost & Sullivan Award
AB SCIEX has been awarded the 2013 Global Market Share Leadership Award for Mass Spectrometry from Frost & Sullivan.
Thursday, September 12, 2013
AB SCIEX and LECO Announces Co-marketing Agreement
Bundled solutions leverage the synergy between two technology leaders.
Thursday, July 04, 2013
AB SCIEX Academic Partnership Program Funds University of Texas Southwestern Researcher
AB SCIEX is supporting the lipidomics research of Jeff McDonald, Ph.D., an associate professor in the Department of Molecular Genetics at the University of Texas Southwestern Medical Center.
Wednesday, November 14, 2012
AB SCIEX and UOW to Collaborate
A research partnership between AB SCIEX and the University of Wollongong will develop lipid analysis capabilities, including the most definitive and comprehensive identification of double bond position in lipids.
Friday, September 21, 2012
AB Sciex Agrees for Sigma-Aldrich® to Distribute iChemistry™ Solutions
Broadens availability of mass spectrometry-based tagging chemistries to biologists and chemists worldwide.
Wednesday, September 12, 2012
AB SCIEX and Premier Biosoft Collaborate on Lipidomics Software
PREMIER Biosoft and AB SCIEX collaborate by offering data analysis solutions for lipidomics.
Monday, June 04, 2012
AB SCIEX Announces Academic Partnership Program
The program aims to increase the number of scientists who benefit from the company’s assistance and resources for advancing research in proteomics, metabolomics and lipidomics.
Wednesday, April 04, 2012
AB SCIEX Announces Academic Partnership Program to Support Biological Research
Focus on proteomics, metabolomics and lipidomics to accelerate promising work in science and biomedical studies.
Wednesday, March 28, 2012
AB SCIEX Expands Commercial Operations in Brazil
The expansion will support the increasing use of mass spectrometry for food safety testing, environmental analysis, academic research, drug development, forensic toxicology and clinical research.
Monday, March 19, 2012
Scientific News
How Different People Respond To Aspirin
Study findings could be used to help identify those who would benefit most from aspirin use.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
A Metabolic Twist that Drives Cancer Survival
A novel metabolic pathway that helps cancer cells thrive in conditions that are lethal to normal cells has been identified.
Liver-On-Chip Tracks Dynamics of Cellular Function
Hebrew University’s liver-on-chip platform is uniquely able to monitor metabolic changes indicating mitochondrial damage occurring at drug concentrations previously regarded as safe.
Living Off the Fat of the Land
Do cancer cells synthesize the parts for new cells or scavenge them from the environment?
Liver Disease, Obesity Linked
Kanazawa University researchers find similarities in the impeded signalling between central insulin activity and glucose production in the liver for both obese mice and mice that have had the vagus nerve removed.
Decoding Ties Between Vascular Disease, Alzheimer’s
NIH consortium uses big data, team science to uncover complex interplay of factors.
Gene Identified that May Worsen Cancer Outcome
Some patients with breast cancer, lung cancer and leukaemia seem to fare poorly after treatment because of the effects of a particular gene, a new study finds.
‘Big Data’ Drills Down Into Metabolic Details
Rice University bioengineers introduce efficient way to analyze, compare tissue-specific pathways.
New Approach to Curbing Cancer Cell Growth
Using a new approach, scientists at The Scripps Research Institute (TSRI) and collaborating institutions have discovered a novel drug candidate that could be used to treat certain types of breast cancer, lung cancer and melanoma.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!